• br Introduction The identification of genetic

  2019-12-20

  

  Introduction The identification of genetic variants that influence susceptibility to Parkinson\'s disease (PD) determines functional studies, the generation of model systems and directs therapeutic strategies. To date, classical candidate gene association studies and genome-wide approaches have f

• Several reports have exploited the application of HRM for de

  2019-12-20

  

  Several reports , , , , have exploited the application of HRM for detecting differentially methylated DNA. Even though DNA methylation analysis by HRM cannot determine the methylation status of individual CpGs, it does provide a robust and inexpensive method to differentiate DNA based on the overal

• As described above when EGCG

  2019-12-19

  

  As described above, when EGCG was orally administered, CYP3A expression in the liver decreased; however, the CYP3A expression level in the intestine was unchanged (Fig. 3). Although we remain speculative, one reason for this may be that because the level of intestinal bacteria in the upper part of t

• Decitabine Another well established visceral action

  2019-12-19

  

  Another well-established visceral action of CRF and urocortin administered peripherally is the long-lasting lowering of blood pressure observed in various species ranging from rodents to humans [22]. Existing evidence suggests that the hypotensive action of CRF and urocortin is mediated by the inter

• Carnitine acetyltransferase CrAT transesterifies short chain

  2019-12-19

  

  Carnitine acetyltransferase (CrAT) transesterifies short-chain acyl-CoAs, and is located both in mitochondria and peroxisomes. In yeasts and mammals this protein is the product of a single gene [20,21] and the sorting to different organelles is evolutionary conserved, although the mechanism of diffe

• The causes of POD are

  2019-12-19

  

  The causes of POD are complex, and not entirely clear. Androsova et al, believed that the main molecular mechanism of POD is a central cholinergic deficiency caused by deregulation of cholinergic anti-inflammatory pathways leading to increased inflammation. The cholinergic anti-inflammatory pathway,

• aurora kinase inhibitor RNA seq results also support the sim

  2019-12-19

  

  RNA-seq results also support the similarity between ESC- and YS-derived B-1 progenitors. Bmi1 expression, known as an important gene for self-renewal ability in stem cells, was reduced in ESC-derived B cells compared with YS-derived B cells, and Bmi1 overexpression improved the engraftment of ESC-de

• br Acknowledgements br Introduction Ischemic retinopathy is

  2019-12-19

  

  Acknowledgements Introduction Ischemic retinopathy is common to the major causes of blindness, including proliferative diabetic retinopathy, venous occlusion, and retinopathy of prematurity. The hypoxia that follows retinal capillary obliteration drives deregulated growth of new blood vessels

• Acknowledgments br Introduction Steroidogenesis the process

  2019-12-19

  

  Acknowledgments Introduction Steroidogenesis, the process of testosterone synthesis, occurs in the adrenal cortex, testis and ovary, and it is controlled by luteinizing hormone (LH), which is synthesized and secreted from the pituitary (Hanukoglu, 1992, Payne and Youngblood, 1995). In the testis

• Nimodipine is an L type calcium channel antagonist that redu

  2019-12-19

  

  Nimodipine is an L-type calcium channel antagonist that reduces excessive calcium influx during pathological conditions, contributing to its neuroprotective properties (Zornow and Prough, 1996; Kobayashi and Mori, 1998). Autophagy can be induced by increased [Ca2+] (Rami et al., 2008). Nimodipine si

• 14520 milliliters to liters br Mechanisms of acquired resist

  2019-12-19

  

  Mechanisms of acquired resistance to 1st and 2nd generation EGFR inhibitors After treatment with first or second generation EGFR TKIs, virtually all patients after approximately 12 months develop acquired resistance (AR). Different mechanisms of AR to EGFR TKIs have been reported to date and may

• ELUXA HM EMSI is an ongoing pivotal Phase II global

  2019-12-19

  

  ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp

• The possibility of harm with DPP

  2019-12-18

  

  The possibility of harm with DPP-4 inhibitors in patients with clinically overt heart failure has been recently highlighted by the results of the VIVIDD (Vildagliptin in Ventricular Dysfunction Diabetes) trial (68), the only trial to date that has been designed to evaluate the effects of a DPP-4 inh

• ATRX belongs to the switch sucrose non

  2019-12-18

  

  ATRX belongs to the switch/sucrose non-fermenting (SWI/SNF) chromatin remodeling family, mutations in which cause syndromal mental retardation and downregulation of α-globin expression (Gibbons et al., 1995). Most of these mutations are located in two highly conserved regions of the ATRX protein: a

• In glioblastoma methylation of pMGMT is predictive

  2019-12-18

  

  In glioblastoma, methylation of pMGMT is predictive of the efficacy of temozolomide with an increased survival [22], [23], [24], [25]. As in glioblastoma [24], [26], [27], [28], pMGMT methylation assessed by pyrosequencing (with immunochemistry, IHC) is the most effective and reproducible technique

15115 records 933/1008 page Previous Next First page 上5页 931932933934935 下5页 Last page